Skip to main content
Nintedanib in Myositis Associated - Interstitial Lung Disease (MINT)
Toggle navigation
MINT Home
Introduction
Objectives
Study Design
Novel Aspects
Notable Endpoints
Inclusion/Exclusion
Compensation
Trial Contacts
Participating Sites
ClinicalTrials.gov
MINT Home
Introduction
Objectives
Study Design
Novel Aspects
Notable Endpoints
Inclusion/Exclusion
Compensation
Trial Contacts
Participating Sites
ClinicalTrials.gov
Compensation
The total compensation for the study is $300.